Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Eva Hoster, Marie-Helene Delfau, Elizabeth A. Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Lothar Kanz, Pierre Feugier, Kai Huebel, Christian Schmidt, Vincent Ribrag, Hanneke Kluin-Nelemans, Martin Dreyling, Christiane Pott

Blood (2022) 140 (Supplement 1): 1304–1306.

https://doi.org/10.1182/blood-2022-159932

Published: 2022

Journal Articles

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

Marie-Helene Delfau, Elizabeth A. Macintyre, Mary B. Callanan, Christiane Pott, Vincent H.J. Van Der Velden, Christa Homburg, Ramon Garcia-Sanz, Paula Gameiro, Maria Gomes Da Silva, Wolfram Klapper, Lucie Oberic, Pierre Feugier, Violaine Safar, Olivier Casasnovas, Martin H. Dreyling, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 40.

https://doi.org/10.1182/blood-2021-145288

Published: 2021

Journal Articles

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

Blood (2021) 138 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2021-147697

Published: 2021

Journal Articles

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

David Sibon, Sherine Khater, Julie Bruneau, Chantal Brouzes, Ludovic Lhermitte, Thierry Jo Molina, Guillaume Cartron, Veronique Morel, Georgia Malamut, Adrien Chauchet, Franck Morschhauser, Baptiste Perard, Jean-Michel Boulet, Anne-Cécile Gauchy, Nadine Cerf-Bensussan, Elizabeth A. Macintyre, Vahid Asnafi, Christophe Cellier, Olivier Hermine

Blood (2021) 138 (Supplement 1): 136.

https://doi.org/10.1182/blood-2021-153709

Published: 2021

Journal Articles

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Alexandra traverse-Glehen, MD PhD, Antoine Martin, MD PhD, Remy Gressin, MD, Vincent Ribrag, MD, Catherine Thieblemont, MD PhD, Marie-Helene Delfau-Larue, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Mary Callanan, MD, Steven Le Gouill, MDPhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 4036.

https://doi.org/10.1182/blood.V130.Suppl_1.4036.4036

Published: 2017

Journal Articles

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Morgane Cheminant, MD, Julie Bruneau, MD PhD, Georgia Malamut, MD PhD, David Sibon, Nicolas Guegan, Sascha Cording, PhD, Amélie Trinquand, MD PhD, Nicole Brousse, MD PhD, Sherine Khater, MD, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Vahid Asnafi, MD PhD, Laurent Pouyet, PhD, Florence Lhospice, PharmD, Thierry Jo Molina, MDPhD, Bertrand Meresse, PhD, Christophe Cellier, MD PhD, Nadine Cerf-Bensussan, MD PhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 2820.

https://doi.org/10.1182/blood.V130.Suppl_1.2820.2820

Published: 2017

Journal Articles

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

Blood (2011) 117 (24): 6650–6659.

https://doi.org/10.1182/blood-2011-02-336842

Published: 2011

Includes: Supplemental data

Journal Articles

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 4188.

https://doi.org/10.1182/blood.V116.21.4188.4188

Published: 2010

Journal Articles

R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

Christiane Pott, Eva Hoster, Kheira Beldjord, Elizabeth A. Macintyre, Sebastian Böttcher, Vahid Asnafi, Reiner Siebert, Anne Plonquet, Evelyne Callet-Bauchut, Vincent Ribrag, Wolfram Klapper, Francoise Berger, Michael Unterhalt, Michael Kneba, Wolfgang Hiddemann, Martin H. Dreyling, Olivier Hermine, Marie-Helene Delfau

Blood (2010) 116 (21): 965.

https://doi.org/10.1182/blood.V116.21.965.965

Published: 2010

Journal Articles

Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia

Blood (2010) 116 (21): 91.

https://doi.org/10.1182/blood.V116.21.91.91

Published: 2010

Journal Articles

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Blood (2007) 110 (11): 1427.

https://doi.org/10.1182/blood.V110.11.1427.1427

Published: 2007

Journal Articles

Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.

Claus Meyer, PhD, Eric Kowarz, Wajih Brahim, MD, Renate Grümayer, MD, Raouf Ben-Abdelali, MD, Etienne De Braekeleer, Marc De Braekeleer, PhD, Elizabeth A. Macintyre, PhD, Eric Delabesse, PhD, Theo Dingermann, PhD, Thomas Klingebiel, MD, Rolf Marschalek, PhD

Blood (2007) 110 (11): 978.

https://doi.org/10.1182/blood.V110.11.978.978

Published: 2007

Journal Articles

PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.

Blood (2007) 110 (11): 2806.

https://doi.org/10.1182/blood.V110.11.2806.2806

Published: 2007

Journal Articles

Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.

Romain Guièze, Aline Renneville, Jean-Michel Cayuela, Raouf Ben Abdelali, Nicolas Boissel, Marie-Thérèse Rubio, Françoise Mazingue, Elizabeth A. Macintyre, François Sigaux, Pierre Fenaux, Hervé Dombret, Claude Preudhomme

Blood (2007) 110 (11): 3496.

https://doi.org/10.1182/blood.V110.11.3496.3496

Published: 2007

Journal Articles

Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs

Julie Bergeron, Emmanuelle Clappier, Isabelle Radford, Agnès Buzyn, Corinne Millien, Gwendoline Soler, Paola Ballerini, Xavier Thomas, Jean Soulier, Hervé Dombret, Elizabeth A. Macintyre, Vahid Asnafi

Blood (2007) 110 (7): 2324–2330.

https://doi.org/10.1182/blood-2007-04-079988

Published: 2007

Includes: Supplemental data

Journal Articles

Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL

Willem A. Dik, Bertrand Nadel, Grzegorz K. Przybylski, Vahid Asnafi, Piotr Grabarczyk, Jean Marc Navarro, Brenda Verhaaf, Christian A. Schmidt, Elizabeth A. Macintyre, Jacques J. M. van Dongen, Anton W. Langerak

Blood (2007) 110 (1): 388–392.

https://doi.org/10.1182/blood-2006-12-064816

Published: 2007

Includes: Supplemental data

NARROW

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.

PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.

Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.

Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs

Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only